Prostate carcinoma High risk
Item
high risk prostate cancer as defined as one of the following:
boolean
C0600139 (UMLS CUI [1,1])
C0332167 (UMLS CUI [1,2])
TNM clinical staging
Item
1. clinical t2b-t4
boolean
C3258246 (UMLS CUI [1])
Gleason score
Item
2. gleason sum score 8-10
boolean
C3203027 (UMLS CUI [1])
Prostate specific antigen measurement | Gleason score
Item
3. psa more than 20 and gleason sum score 7
boolean
C0201544 (UMLS CUI [1])
C3203027 (UMLS CUI [2])
TNM clinical staging | Biopsy Quantity | Gleason score
Item
4. in addition, clinical t2a patients are eligible if 5 or more biopsies contain gleason 4+3 cancer (minimum of 10 biopsies total required)
boolean
C3258246 (UMLS CUI [1])
C0005558 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C3203027 (UMLS CUI [3])
Neoplasm Metastasis Absent | Physical Examination | Plain chest X-ray | Bone scan | CT of abdomen | CT of Pelvis
Item
no evidence of metastatic disease within 60 days of enrollment, confirmed by physical examination, chest x-ray, bone scan, and computed tomography of the abdomen and pelvis
boolean
C0027627 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0031809 (UMLS CUI [2])
C0039985 (UMLS CUI [3])
C0203668 (UMLS CUI [4])
C0412620 (UMLS CUI [5])
C0412628 (UMLS CUI [6])
ECOG performance status
Item
ecog performance status of 0, 1 or 2
boolean
C1520224 (UMLS CUI [1])
Therapeutic radiology procedure Prostate carcinoma | Cytotoxic therapy Prostate carcinoma | Biological treatment Prostate carcinoma | major surgery | Hormone Therapy | Finasteride | Voiding Symptoms Obstructive
Item
concurrent or prior treatment with radiation, cytotoxic, biologic therapy for prostate cancer; any major surgery within four weeks, prior hormonal therapy (except finasteride for obstructive voiding symptoms)
boolean
C1522449 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0677881 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
C1531518 (UMLS CUI [3,1])
C0600139 (UMLS CUI [3,2])
C0679637 (UMLS CUI [4])
C0279025 (UMLS CUI [5])
C0060389 (UMLS CUI [6])
C0042034 (UMLS CUI [7,1])
C1457887 (UMLS CUI [7,2])
C0549186 (UMLS CUI [7,3])
Major surgery | Incisional biopsy | Traumatic injury | Major surgery Anticipated | Minor Surgical Procedures | Fine needle aspiration biopsy | Core needle biopsy
Item
major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to day 0
boolean
C0679637 (UMLS CUI [1])
C0184922 (UMLS CUI [2])
C3263723 (UMLS CUI [3])
C0679637 (UMLS CUI [4,1])
C3840775 (UMLS CUI [4,2])
C0038904 (UMLS CUI [5])
C1510483 (UMLS CUI [6])
C1318309 (UMLS CUI [7])
CNS metastases | Metastatic malignant neoplasm to brain
Item
presence of central nervous system or brain metastases
boolean
C0686377 (UMLS CUI [1])
C0220650 (UMLS CUI [2])
Blood pressure
Item
blood pressure of >150/100 mmhg
boolean
C1271104 (UMLS CUI [1])
Myocardial Infarction
Item
history of myocardial infarction within 6 months
boolean
C0027051 (UMLS CUI [1])
Cerebrovascular accident
Item
history of stroke within 6 months
boolean
C0038454 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs | bevacizumab
Item
current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a genentech-sponsored bevacizumab cancer study
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0796392 (UMLS CUI [3])